Urs Vögeli replaces Andreas Gerber as Managing Director at Johnson & Johnson
06.08.2024 13:00
Urs Vögeli has been Chairman of the Management Board of Janssen-Cilag GmbH, the pharmaceutical segment of Johnson & Johnson in Germany, since August 1, 2024. He succeeds Andreas Gerber, who is moving to the company's US headquarters as Worldwide Vice President of Oncology.
Vögeli reports to Company Group Chairman EMEA, Kris Sterkens, and is a member of the EMEA Leadership Team. A native of Switzerland, he joins from Johnson & Johnson Australia and New Zealand (ANZ), where he served as Area Director since 2022. Prior to that, he led Johnson & Johnson's business in Switzerland for three years, among other roles. In addition to his previous management roles, Vögeli was active in relevant industry associations, including as Vice President of the Swiss pharmaceutical association Interpharma.
Urs Vögeli has 15 years of international experience in the pharmaceutical industry. He is familiar with the German healthcare system from his time as Commercial Director of Oncology and Hematology and a member of the German Executive Board, where he served until 2018. Prior to his career at Johnson & Johnson, he held various positions at international research-based pharmaceutical companies.
"Johnson & Johnson is a key driver of medical progress. To ensure that this progress reliably reaches people and patients can rely on having access to the most suitable therapies at the right time, I will work with all relevant partners in the healthcare system to promote early access to medical innovations and a competitive pharmaceutical location in Germany," said Vögeli.